MRNA
Moderna, Inc.
Biotechnology · Healthcare · United States
221.72
close · 2026-10-30
value
80
cheaper than peers80
quality
37
stronger fundamentals37
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 9.1% | 96 |
| cash flow yield, 3 years ago | 5.2% | 93 |
| earnings yield, 2 years ago | -5.6% | 75 |
| earnings yield, 1 year ago | -4.2% | 74 |
| cash flow yield, latest year | -2.3% | 72 |
| earnings yield, latest year | -3.3% | 70 |
| cash flow yield, 1 year ago | -4.6% | 69 |
| cash flow yield, 2 years ago | -4.3% | 67 |
| price to sales | 39.73× | 26 |
| price to book | 13.08× | 17 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -39.0% | 61 |
| debt to equity | 19.0% | 49 |
| revenue growth | 2.1% | 37 |
| operating margin | -557.9% | 31 |
4 of 4 measures available
Facts
| market cap | $89B |
| free cash flow | $299.2M |
| employees | 4,700 |
| first trade | 2018-12-07 |
| next earnings | 2026-11-06 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -7.26 | -9.28 | -12.33 | 20.12 |
| free cash flow | -$2.08B | -$4.05B | -$3.83B | $4.58B |
| net income | -$2.82B | -$3.56B | -$4.71B | $8.36B |
| revenue | $1.92B | $3.20B | $6.75B | $18.88B |
| unusual items | -$5.0M | -$56.0M | -$72.0M | -$20.0M |